RAS is the most common oncogene in human cancer. Activating mutations in one of the three human RAS gene isoforms (KRAS, HRAS or NRAS) are present in about one-fourth of all cancers. For example, mutant KRAS is found in 98% of pancreatic ductal adenocarcinomas, 52% of colon cancers, and 32% of lung adenocarcinomas. Just for these three cancer types alone, that means that cancers with mutant KRAS are diagnosed in more than 170,000 people each year in the US and cause more than 120,000 deaths. There are no FDA-approved direct RAS protein inhibitors currently available. Drugs that target signaling downstream of RAS are available but have shown disappointing clinical activity, most likely because RAS is a “hub” that activates multiple effectors and blocking any single pathway (or even two) will be ineffective. Qualigen’s RAS-F is a small molecule RAS oncogene protein-protein inhibitor that has been shown to block RAS mutations in early studies; as such, this investigational drug product is under evaluation for its inhibitory effects in tumor formation and the company intends to investigate safety and efficacy in a variety of cancers, especially pancreatic, colorectal, and lung cancers.